To study the absorption, distribution, metabolism and excretion of AZD1305
Study identifier:D3190C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open, Randomised, Single-Centre, Crossover Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) after Oral and Intravenous Administration of 14C-labelled and Non-labelled AZD1305 to Healthy Male Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1305
Sex
Male
Actual Enrollment
10
Study type
Interventional
Age
35 Years - 55 Years
Date
Study Start Date: 01 Apr 2008
Primary Completion Date: 01 May 2008
Study Completion Date: 01 May 2008
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: A AZD1305 given as oral solution | Drug: AZD1305 oral solution, single dose |
| Experimental: B AZD1305 given as iv infusion | Drug: AZD1305 iv infusion, single dose |
Contacts
Investigators
Principal Investigator
Helen Lunde
AstraZeneca R&D Mölndal, Sweden
